表紙
市場調查報告書

便秘性大腸激躁症 (IBS-C) 治療藥的全球市場的未來預測

Global IBS-C Drug Market Forecast 2020-2028

出版商 Inkwood Research 商品編碼 535785
出版日期 內容資訊 英文 211 Pages
商品交期: 2-3個工作天內
價格
便秘性大腸激躁症 (IBS-C) 治療藥的全球市場的未來預測 Global IBS-C Drug Market Forecast 2020-2028
出版日期: 2020年02月21日內容資訊: 英文 211 Pages
簡介

本報告提供全球便秘性大腸激躁症 (IBS-C) 治療藥的市場未來展望相關分析,疾病概要和市場基本結構,主要的市場推動及阻礙要素,市場整體及各類型、各處方手段、各地區的市場趨勢預測 (總計10年份),目前市場向心力的水準企業間競爭趨勢,主要企業簡介等調查。

第1章 分析範圍

第2章 分析方法

第3章 摘要整理

第4章 市場概要

  • 市場定義
  • 市場概要
  • 有前途的投資方案
  • 主要的治療藥製造商在市場上的定位
  • 市場的推動要素
  • 市場的阻礙要素
  • 市場機會
  • 課題

第5章 全球IBS-C治療藥市場:藥物的各類型 (以金額為準,今後9年份)

  • 概要
    • LUBIPROSTONE
    • LINACLOTIDE
    • 興奮性瀉藥
    • 滲透性瀉藥
    • 其他 PSYLLIUM):質性資訊
  • 開發平台上的治療藥分析:PLECANATIDE

第6章 全球IBS-C治療藥市場:各處方手段 (以金額為準,今後9年份)

  • 處方藥
    • 品牌藥
    • 學名藥
  • 成藥

第7章 主要指標

  • 波特的五力分析
  • 供應商環境
  • 市場機會矩陣

第8章 全球IBS-C治療藥市場:各地區 (以金額為準,今後9年份)

  • 北美 (美國,加拿大)
  • 歐洲 (英國,德國等)
  • 亞太地區 (中國,日本等)
  • 其他的國家 (RoW:中東、非洲,南美等)

第9章 企業簡介

  • CATALENT PHARMACEUTICALS SOLUTIONS
    • 概要
    • 產品系列
    • SCOT分析
    • 策略發展情形
  • NESTLE
  • ABBOTT LABORATORIES
  • SYNERGY PHARMACEUTICALS
  • SUCAMPO PHARMACEUTICALS
  • NOVARTIS PHARMA AG
  • Astellas Pharma Inc.
  • ARDELYX, INC.
  • SYNTHETIC BIOLOGICS, INC.
  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED
  • BAMA-GEVE, SLU
  • FERRING BV
  • IRONWOOD PHARMACEUTICALS, INC.
  • SALIX PHARMACEUTICALS LTD
  • NORGINE B.V.
  • PROMETHEUS LABORATORIES INC.
  • ACTAVIS NORDIC A/S
  • ALBIREO PHARMA INC
  • YUHAN CORP
  • ASTRAZENECA PLC
  • THE MENARINI GROUP
  • 小野藥品工業

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 6396

KEY FINDINGS:

The global IBS-C drug market is estimated to grow and record a CAGR of 9.21% during the forecast period, 2020-2028. The factors augmenting the global market growth are growing lifestyle-oriented diseases, an increase in healthcare expenditure, severe gastrointestinal infection, an increasing number of patients suffering from depression, and medical advancements.

MARKET INSIGHTS:

Irritable bowel syndrome (IBS) is prevalent in the general population and has affected adversely in terms of substantial and socio-economic impact. There are about 10-20% of the population experiencing symptoms of IBS, but 15% of affected individuals seek medical treatment. Due to highly prevailing modern dietary habits, such as intake of fried foods, insoluble fiber, and excessive consumption of alcohol and caffeine, there is a rise in the number of people suffering from IBS. The factors acting as market constraints are strict FDA regulations and ignorance among people. There are some serious after-effects of the drugs used to treat IBS. Thus, the industry suffers from strict regulations from the FDA and other regulatory authorities, leading to many drugs being called off from the market and or not approved by the FDA. Competition is high among the existing players in the market due to the presence of a few approved therapies. Companies are competing with each other by providing the products with similar features at similar or lower prices, and also by acquiring major companies.

REGIONAL INSIGHTS:

The global IBS-C drug market is analyzed geographically on the basis of markets situated across the region of North America, Europe, Asia Pacific, and the Rest of the World. As of 2019, the region of North America holds the largest market share in terms of revenue, and continues the trend by the end of the forecast period. This is attributed to the government initiative to improve the healthcare sector by providing the latest technological medication and advanced treatment support.

COMPETITIVE INSIGHTS:

Novartis, Teva Pharmaceutical Industries, Catalent Pharma Solutions, Actavis Nordic, Yuhan Corp., etc. are some of the prominent players registering their presence in the global market.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
    • 3.2.2. IBS CAN BE A HERITABILITY ISSUE
    • 3.2.3. AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
  • 3.3. KEY RESTRAINTS
    • 3.3.1. STRICT FDA REGULATIONS
    • 3.3.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE

4. KEY ANALYTICS

  • 4.1. KEY INVESTMENT INSIGHTS
  • 4.2. PORTER'S FIVE FORCE ANALYSIS
    • 4.2.1. BUYER POWER
    • 4.2.2. SUPPLIER POWER
    • 4.2.3. SUBSTITUTION
    • 4.2.4. NEW ENTRANTS
    • 4.2.5. INDUSTRY RIVALRY
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE
  • 4.5. REGULATORY FRAMEWORK

5. MARKET BY PRESCRIPTION TYPE

  • 5.1. PRESCRIBED
    • 5.1.1. BRANDED
    • 5.1.2. GENERIC
  • 5.2. OVER THE COUNTER

6. MARKET BY DRUG TYPE

  • 6.1. LUBIPROSTONE
  • 6.2. LINACLOTIDE
  • 6.3. STIMULANT LAXATIVES
    • 6.3.1. BISACODYL
    • 6.3.2. SENNA
  • 6.4. OSMOTIC LAXATIVES
    • 6.4.1. LACTULOSE
    • 6.4.2. POLYETHYLENE GLYCOL
  • 6.5. OTHER DRUG TYPES

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. UNITED STATES
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. UNITED KINGDOM
    • 7.2.2. GERMANY
    • 7.2.3. FRANCE
    • 7.2.4. ITALY
    • 7.2.5. RUSSIA
    • 7.2.6. BELGIUM
    • 7.2.7. POLAND
    • 7.2.8. REST OF EUROPE
  • 7.3. ASIA PACIFIC
    • 7.3.1. CHINA
    • 7.3.2. JAPAN
    • 7.3.3. INDIA
    • 7.3.4. SOUTH KOREA
    • 7.3.5. INDONESIA
    • 7.3.6. THAILAND
    • 7.3.7. VIETNAM
    • 7.3.8. AUSTRALIA & NEW ZEALAND
    • 7.3.9. REST OF ASIA PACIFIC
  • 7.4. REST OF WORLD
    • 7.4.1. LATIN AMERICA
    • 7.4.2. MIDDLE EAST & AFRICA

8. COMPANY PROFILES

  • 8.1. CATALENT PHARMACEUTICALS SOLUTIONS
  • 8.2. ABBOTT LABORATORIES
  • 8.3. NOVARTIS PHARMA AG
  • 8.4. ASTELLAS PHARMACEUTICALS
  • 8.5. ARDELYX, INC.
  • 8.6. SYNTHETIC BIOLOGICS, INC.
  • 8.7. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
  • 8.8. BAMA-GEVE, SLU
  • 8.9. FERRING BV
  • 8.10. IRONWOOD PHARMACEUTICALS, INC.
  • 8.11. SALIX PHARMACEUTICALS LTD.
  • 8.12. NORGINE B.V.
  • 8.13. PROMETHEUS LABORATORIES, INC.
  • 8.14. ALBIREO PHARMA, INC.
  • 8.15. YUHAN CORP.
  • 8.16. ASTRAZENECA PLC
  • 8.17. THE MENARINI GROUP
  • 8.18. ONO PHARMACEUTICAL CO. LTD.
  • 8.19. ACTAVIS NORDIC A/S

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - IBS-C DRUG
  • TABLE 2: REGULATORY FRAMEWORK
  • TABLE 3: GLOBAL IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 4: GLOBAL IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 5: GLOBAL PRESCRIBED MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 6: GLOBAL PRESCRIBED MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 7: GLOBAL IBS-C DRUG MARKET, BY PRESCRIBED, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 8: GLOBAL IBS-C DRUG MARKET, BY PRESCRIBED, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 9: PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
  • TABLE 10: GLOBAL BRANDED MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: GLOBAL BRANDED MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 12: GLOBAL GENERIC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 13: GLOBAL GENERIC MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 14: GLOBAL OVER THE COUNTER MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 15: GLOBAL OVER THE COUNTER MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 16: GLOBAL IBS-C DRUG MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: GLOBAL IBS-C DRUG MARKET, BY DRUG TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 18: PRODUCT PROFILE (LUBIPROSTONE)
  • TABLE 19: GLOBAL LUBIPROSTONE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 20: GLOBAL LUBIPROSTONE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 21: PRODUCT PROFILE (LINACLOTIDE)
  • TABLE 22: GLOBAL LINACLOTIDE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 23: GLOBAL LINACLOTIDE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 24: GLOBAL STIMULANT LAXATIVES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 25: GLOBAL STIMULANT LAXATIVES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 26: GLOBAL IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 27: GLOBAL IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 28: PRODUCT PROFILE (BISACODYL)
  • TABLE 29: GLOBAL BISACODYLMARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 30: GLOBAL BISACODYLMARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 31: PRODUCT PROFILE (SENNA)
  • TABLE 32: GLOBAL SENNA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 33: GLOBAL SENNA MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 34: GLOBAL OSMOTIC LAXATIVES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 35: GLOBAL OSMOTIC LAXATIVES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 36: GLOBAL IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 37: GLOBAL IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 38: PRODUCT PROFILE (LACTULOSE)
  • TABLE 39: GLOBAL LACTULOSE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 40: GLOBAL LACTULOSE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 41: PRODUCT PROFILE (POLYETHYLENE GLYCOL)
  • TABLE 42: GLOBAL POLYETHYLENE GLYCOL MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 43: GLOBAL POLYETHYLENE GLYCOL MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 44: PRODUCT PROFILE (PSYLLIUM)
  • TABLE 45: GLOBAL OTHER DRUG TYPES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 46: GLOBAL OTHER DRUG TYPES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 47: GLOBAL IBS-C DRUG MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 48: GLOBAL IBS-C DRUG MARKET, BY GEOGRAPHY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 49: NORTH AMERICA IBS-C DRUG MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 50: NORTH AMERICA IBS-C DRUG MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 51: EUROPE IBS-C DRUG MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 52: EUROPE IBS-C DRUG MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 53: ASIA PACIFIC IBS-C DRUG MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 54: ASIA PACIFIC IBS-C DRUG MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 55: REST OF WORLD IBS-C DRUG MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 56: REST OF WORLD IBS-C DRUG MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: DRUGS PULLED OFF FROM THE MARKET
  • FIGURE 2: KEY INVESTMENT INSIGHTS
  • FIGURE 3: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 4: OPPORTUNITY MATRIX
  • FIGURE 5: VENDOR LANDSCAPE
  • FIGURE 6: GLOBAL IBS-C DRUG MARKET, GROWTH POTENTIAL, BY PRESCRIPTION TYPE, IN 2019
  • FIGURE 7: GLOBAL IBS-C DRUG MARKET, PRESCRIBED, 2020-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL IBS-C DRUG MARKET, BRANDED, 2020-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL IBS-C DRUG MARKET, GENERIC, 2020-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL IBS-C DRUG MARKET, OVER THE COUNTER, 2020-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL IBS-C DRUG MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2019
  • FIGURE 12: GLOBAL IBS-C DRUG MARKET, LUBIPROSTONE, 2020-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL IBS-C DRUG MARKET, LINACLOTIDE, 2020-2028 (IN $ MILLION)
  • FIGURE 14: GLOBAL IBS-C DRUG MARKET, STIMULANT LAXATIVES, 2020 -2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)
  • FIGURE 16: GLOBAL IBS-C DRUG MARKET, SENNA, 2020-2028 (IN $ MILLION)
  • FIGURE 17: GLOBAL IBS-C DRUG MARKET, OSMOTIC LAXATIVES, 2020 -2028 (IN $ MILLION)
  • FIGURE 18: GLOBAL IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)
  • FIGURE 19: GLOBAL IBS-C DRUG MARKET, POLYETHYLENE GLYCOL, 2020-2028 (IN $ MILLION)
  • FIGURE 20: GLOBAL IBS-C DRUG MARKET, OTHER DRUG TYPES, 2020 -2028 (IN $ MILLION)
  • FIGURE 21: NORTH AMERICA IBS-C DRUG MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 22: UNITED STATES IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 23: CANADA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 24: EUROPE IBS-C DRUG MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 25: UNITED KINGDOM IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 26: GERMANY IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 27: FRANCE IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 28: ITALY IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 29: RUSSIA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 30: BELGIUM IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 31: POLAND IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 32: REST OF EUROPE IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 33: ASIA PACIFIC IBS-C DRUG MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 34: CHINA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 35: CHINESE MEDICINE TCM TREATMENT FOR IBS
  • FIGURE 36: JAPAN IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 37: INDIA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 38: SOUTH KOREA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 39: INDONESIA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 40: THAILAND IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 41: VIETNAM IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 42: AUSTRALIA & NEW ZEALAND IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 43: REST OF ASIA PACIFIC IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 44: REST OF WORLD IBS-C DRUG MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 45: LATIN AMERICA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 46: MIDDLE EAST & AFRICA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)